Last reviewed: June 24, 2026 Last updated: June 24, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The Phase 3 results are promising, but most of the programme is still running, and the long-term cardiovascular outcomes data wont be available until 2028 at the earliest
Building a complete protocol budget Cheap retatrutide is only one line item in a complete protocol budget
While Indian pharma companies jostle for a share of the rapidly unfolding #semaglutide generics market #EliLilly's next-generation incretin therapy #retatrutide (famously #TripleG) is seen as a game changer with stunning results reported from its recent late-stage clinical trials
Any information presented regarding Retatrutide reflects findings from published scientific literature and preclinical or clinical research sources
Weeks 2-3 (1.2-1.8mg): Appetite suppression becomes more pronounced